| __timestamp | Bristol-Myers Squibb Company | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 11947000000 | 23068000 |
| Thursday, January 1, 2015 | 12651000000 | 33277000 |
| Friday, January 1, 2016 | 14481000000 | 184902000 |
| Sunday, January 1, 2017 | 14710000000 | 437411000 |
| Monday, January 1, 2018 | 16014000000 | 827478000 |
| Tuesday, January 1, 2019 | 18067000000 | 934678000 |
| Wednesday, January 1, 2020 | 30745000000 | 951266000 |
| Friday, January 1, 2021 | 36445000000 | 1382097000 |
| Saturday, January 1, 2022 | 36022000000 | 1553153000 |
| Sunday, January 1, 2023 | 34313000000 | 1757661000 |
| Monday, January 1, 2024 | 36351000000 | 2168701000 |
Unleashing insights
In the ever-evolving landscape of biopharmaceuticals, Bristol-Myers Squibb Company (BMY) and Exelixis, Inc. (EXEL) have carved distinct paths over the past decade. From 2014 to 2023, BMY's gross profit surged by nearly 187%, peaking in 2021 with a remarkable 36.4 billion. This growth reflects strategic acquisitions and a robust pipeline of innovative therapies. In contrast, Exelixis, a smaller player, demonstrated a tenfold increase in gross profit, reaching 1.76 billion in 2023. This growth underscores its successful focus on oncology treatments. While BMY's profits dwarf those of Exelixis, the latter's rapid growth trajectory highlights its potential in the competitive biotech sector. As these companies continue to innovate, investors and industry watchers should keep a keen eye on their evolving strategies and market impacts.
Eli Lilly and Company and Bristol-Myers Squibb Company: A Detailed Gross Profit Analysis
Novo Nordisk A/S and Exelixis, Inc.: A Detailed Gross Profit Analysis
Merck & Co., Inc. and Exelixis, Inc.: A Detailed Gross Profit Analysis
Who Generates Higher Gross Profit? Bristol-Myers Squibb Company or BioMarin Pharmaceutical Inc.
Who Generates Higher Gross Profit? Bristol-Myers Squibb Company or Walgreens Boots Alliance, Inc.
Gross Profit Analysis: Comparing Bristol-Myers Squibb Company and MorphoSys AG
Gross Profit Comparison: Bristol-Myers Squibb Company and Ligand Pharmaceuticals Incorporated Trends
Gross Profit Analysis: Comparing Bristol-Myers Squibb Company and Supernus Pharmaceuticals, Inc.
Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Exelixis, Inc.
Gross Profit Analysis: Comparing Exelixis, Inc. and Halozyme Therapeutics, Inc.
Gross Profit Analysis: Comparing Exelixis, Inc. and Jazz Pharmaceuticals plc
Who Generates Higher Gross Profit? Exelixis, Inc. or Supernus Pharmaceuticals, Inc.